Publicado

2018-05-01

Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population

Frecuencia de 14 variantes genéticas asociadas con el riesgo y el tratamiento del cáncer de mama en una población colombiana

DOI:

https://doi.org/10.15446/rcciquifa.v47n2.73971

Palabras clave:

Colombia, pharmacogenomics, breast Cancer (en)
Colombia, farmogénetica, cáncer de mama (es)

Descargas

Autores/as

  • Yeimy Viviana Ariza Márquez Programa de doctorado en Biotecnología, Universidad Nacional de Colombia, sede Bogotá, Colombia
  • Fabio Ancízar Aristizábal Gutiérrez Departamento de Farmacia e Instituto de Biotecnología, Universidad Nacional de Colombia, sede Bogotá, Colombia
  • Alberto Gómez- Gutiérrez Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia.
  • Piedad Elena Gómez Instituto de Referencia Andino, Bogotá, Colombia
  • María Consuelo Casas Gómez Instituto de Referencia Andino, Bogotá, Colombia
  • Ignacio Briceño Balcázar Facultad de Medicina, Universidad de la Sabana, Chía, Colombia

Introduction: Genetic variations have been related to risk and treatment efficacy. Many polymorphisms in breast cancer are known to influence susceptibility, breast cancer risk and treatment outcome. Polymorphisms vary among populations; therefore, local studies are necessary.

Objective: To establish the frequency of polymorphisms associated to breast cancer risk and treatment pharmacogenomics in a group of Colombian individuals.

Methods: Data from microarray profiles including gene polymorphisms associated with breast cancer treatment were retrospectively collected (Pathway Genomics®). The frequency of marker CYP2D6 rs3892097 and a breast cancer panel (CAS8 rs1045485, CHEK21100delC, ESR1 rs2046210, FGFR2 rs1219648, intergenic_2q35rs13387042, intergenic_8q24 rs13281615, MSRP30 rs10941679, TNRC9 rs3803662, AKAP9 rs6964587, LSP1 rs3817198, MAP3K1rs889312, PALBS1592 delT, ESR1 rs3020314) were studied.

Results: Microarray data from 68 men and 92 women were analyzed. All polymorphisms were in Hardy-Weinberg equilibrium. Genotypic frequencies of CYP2D6 rs3892097 C/T, CAS8 rs1045485 G/C, and those of genes included in a breast cancer panel (CAS8 rs1045485, CHEK21100delC, FGFR2rs1219648, intergenic_2q35rs13387042, intergenic_8q24 rs13281615, MSRP30 rs10941679, TNRC9 rs3803662, LSP1 rs3817198, MAP3K1rs889312, PALBS1592 del T, ESR1rs3020314) did not significantly differ from previously published data. ESR1 rs2046210, with allele frequencies of C=0.04 and T=0.02, and AKAP9 rs6964587, with a frequency of A=0.005, were determined as rare.

Conclusions: The population studied was not significantly different in allele distribution from previously reported data at HapMap. Genotypes in Colombian population are similar to other previously studied groups of healthy subjects. Extended use of genotyping pharmacogenetic polymorphisms will prevent toxicity and adverse effects in tamoxifen treatment (for example in CYP2D6 rs3892097). Therefore, therapeutic alternatives should be evaluated based on individual pharmacogenetic studies.

Introducción: las variaciones genéticas se han relacionado con el riesgo y la eficacia del tratamiento. Es sabido que muchos polimorfismos en cáncer de mama influyen en la susceptibilidad, el riesgo de cáncer y el resultado del tratamiento. Los polimorfismos varían entre las poblaciones, y por tanto, es necesario realizar estudios locales.

Objetivo: establecer la frecuencia de polimorfismos asociados al riesgo de cáncer de mama y la farmacogenómica del tratamiento en un grupo de individuos colombianos.

Métodos: los datos de los perfiles de microarreglos, incluidos los polimorfismos genéticos asociados con el tratamiento del cáncer de mama, se obtuvieron de forma retrospectiva (Pathway Genomics®). Se estudiaron la frecuencia del marcador CYP2D6 rs3892097 y un panel de cáncer de mama (CAS8 rs1045485, CHEK21100delC, ESR1 rs2046210, FGFR2 rs1219648, intergenic_2q35rs13387042, intergenic_8q24 rs13281615, MSRP30 rs10941679, TNRC9 rs3803662, AKAP9 rs6964587, LSP1 rs3817198, MAP3K1rs889312, PALBS1592 delT, ESR1 rs3020314).

Resultados: se analizaron los datos de microarreglos de 68 hombres y 92 mujeres. Todos los polimorfismos siguieron el equilibrio Hardy-Weinberg. Las frecuencias fenotípicas de CYP2D6 rs3892097 C/T, CAS8 rs1045485 G/C, y aquellas de los genes incluidos en un panel de cáncer de mama (CAS8 rs1045485, CHEK21100delC, FGFR2rs1219648, intergenic_2q35rs13387042, intergenic_8q24 rs13281615, MSRP30 rs10941679, TNRC9 rs3803662, LSP1 rs3817198, MAP3K1rs889312, PALBS1592 del T, ESR1rs3020314) no difirieron significativamente de los datos publicados previamente. ESR1 rs2046210, con frecuencias alélicas de C = 0,04 y T = 0,02, y AKAP9 rs6964587, con una frecuencia de A = 0,005, se determinaron como raras.

Referencias

C. Romero-Sánchez, A. Gómez-Gutiérrez, P.E. Gómez, M.C. Casas-Gómez, I. Briceño, C677T (RS1801133) MTHFR gene polymorphism frequency in a colombian population, Colombia Médica, 46(2), 75-79 (2015).

O. Fletcher, F. Dudbridge, Candidate gene-environment interactions in breast cancer, BMC Medicine, 12, 195 (2014).

Y. Sun, C. Ye, X. Guo et al., Evaluation of potential regulatory function of breast cancer risk locus at 6q25.1, Carcinogenesis, 37(2), 163-168 (2016).

F. Cui, D. Wu, W. Wang, X. He, M. Wang, Variants of FGFR2 and their associations with breast cancer risk: a HUGE systematic review and meta-analysis. Breast Cancer Res. Treat., 155(2), 313-335 (2016).

E. Sirachainan, S. Jaruhathai, N. Trachu et al., CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients, Pharmgenomics Pers. Med., 5, 149-153 (2012).

A. Cox, A.M. Dunning, M. García-Closas et al., A common coding variant in CASP8 is associated with breast cancer risk, Nat. Genet., 39(3), 352-358 (2007).

T.N. Sergentanis, K.P. Economopoulos, Association of two CASP8 polymorphisms with breast cancer risk: A meta-analysis, Breast Cancer Res. Treat., 120(1), 229-234 (2010).

W. Zheng, J. Long, Y.T. Gao et al., Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1, Nat. Genet., 41(3), 324-328 (2009).

Q. Cai, W. Wen, S. Qu et al., Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry, Cancer Res., 71(4), 1344-1355 (2011).

G. Li, Y.B. Xiang, R. Courtney et al., Association of a single nucleotide polymorphism at 6q25.1,rs2046210, with endometrial cancer risk among Chinese women. Chin. J. Cancer, 30(2), 138-143 (2011).

M. García-Closas, F.J. Couch, S. Lindstrom et al., Genome-wide association studies identify four ER negative-specific breast cancer risk loci, Nat. Genet., 45(4), 392-398 (2013).

H. Liang, X. Yang, L. Chen et al., Heterogeneity of breast cancer associations with common genetic variants in FGFR2 according to the intrinsic subtypes in Southern Han Chinese women, Biomed Res. Int., 2015, 626948 (2015).

S. Siddiqui, S. Chattopadhyay, M.S. Akhtar et al., A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India, PLoS One, 9(10), e110426 (2014).

L. Fejerman, M.C. Stern, E.M. John et al., Interaction between common breast cancer susceptibility variants, genetic ancestry, and nongenetic risk factors in Hispanic women, Cancer Epidemiol. Biomarkers Prev., 24(11), 1731-1738 (2015).

Z. Zhang, A. Zhu, B. Zhang et al., Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer, J. Genet. Genomics, 41(4), 187-195 (2014).

D. Campa, M. Barrdahl, M.M. Gaudet et al., Genetic risk variants associated with in situ breast cancer, Breast Cancer Res., 17, 82 (2015).

Q. Chen, Y. He, C. Liu et al., [Associations between TOX3 rs3803662 polymorphisms and immunological markers of breast cancer], Zhonghua Yi Xue Za Zhi, 95(34), 2783-2786 (2015).

L. Dorling, G.C. Barnett, K. Michailidou et al., Patients with a high polygenic risk of breast cancer do not have an increased risk of radiotherapy toxicity, Clin. Cancer Res., 22(6), 1413-1420 (2016).

R.L. Milne, B. Burwinkel, K. Michailidou et al., Common non-synonymous SNPs associated with breast cancer susceptibility: Findings from the Breast Cancer Association Consortium, Hum. Mol. Genet., 23(22), 6096-6111 (2014).

A. Rudolph, P.A. Fasching, S. Behrens et al., A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density, Breast Cancer Res., 17, 110 (2015).

D.M. Glubb, M.J. Maranian, K. Michailidou et al., Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1, Am. J. Hum. Genet., 96(1), 5-20 (2015).

L. Quan, C.C. Hong, G. Zirpoli et al., Variants of estrogen-related genes and breast cancer risk in European and African American women, Endocr. Relat. Cancer, 21(6), 853-864 (2014).

R.L. Milne, J. Lorenzo-Bermejo, B. Burwinkel et al., 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium, J. Med. Genet., 48(10), 698-702 (2011).

Cómo citar

APA

Ariza Márquez, Y. V., Ancízar Aristizábal Gutiérrez, F., Gómez- Gutiérrez, A., Gómez, P. E., Casas Gómez, M. C. & Briceño Balcázar, I. (2018). Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population. Revista Colombiana de Ciencias Químico-Farmacéuticas, 47(2), 277–288. https://doi.org/10.15446/rcciquifa.v47n2.73971

ACM

[1]
Ariza Márquez, Y.V., Ancízar Aristizábal Gutiérrez, F., Gómez- Gutiérrez, A., Gómez, P.E., Casas Gómez, M.C. y Briceño Balcázar, I. 2018. Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population. Revista Colombiana de Ciencias Químico-Farmacéuticas. 47, 2 (may 2018), 277–288. DOI:https://doi.org/10.15446/rcciquifa.v47n2.73971.

ACS

(1)
Ariza Márquez, Y. V.; Ancízar Aristizábal Gutiérrez, F.; Gómez- Gutiérrez, A.; Gómez, P. E.; Casas Gómez, M. C.; Briceño Balcázar, I. Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population. Rev. Colomb. Cienc. Quím. Farm. 2018, 47, 277-288.

ABNT

ARIZA MÁRQUEZ, Y. V.; ANCÍZAR ARISTIZÁBAL GUTIÉRREZ, F.; GÓMEZ- GUTIÉRREZ, A.; GÓMEZ, P. E.; CASAS GÓMEZ, M. C.; BRICEÑO BALCÁZAR, I. Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population. Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 47, n. 2, p. 277–288, 2018. DOI: 10.15446/rcciquifa.v47n2.73971. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/73971. Acesso em: 22 mar. 2026.

Chicago

Ariza Márquez, Yeimy Viviana, Fabio Ancízar Aristizábal Gutiérrez, Alberto Gómez- Gutiérrez, Piedad Elena Gómez, María Consuelo Casas Gómez, y Ignacio Briceño Balcázar. 2018. «Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population». Revista Colombiana De Ciencias Químico-Farmacéuticas 47 (2):277-88. https://doi.org/10.15446/rcciquifa.v47n2.73971.

Harvard

Ariza Márquez, Y. V., Ancízar Aristizábal Gutiérrez, F., Gómez- Gutiérrez, A., Gómez, P. E., Casas Gómez, M. C. y Briceño Balcázar, I. (2018) «Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population», Revista Colombiana de Ciencias Químico-Farmacéuticas, 47(2), pp. 277–288. doi: 10.15446/rcciquifa.v47n2.73971.

IEEE

[1]
Y. V. Ariza Márquez, F. Ancízar Aristizábal Gutiérrez, A. Gómez- Gutiérrez, P. E. Gómez, M. C. Casas Gómez, y I. Briceño Balcázar, «Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population», Rev. Colomb. Cienc. Quím. Farm., vol. 47, n.º 2, pp. 277–288, may 2018.

MLA

Ariza Márquez, Y. V., F. Ancízar Aristizábal Gutiérrez, A. Gómez- Gutiérrez, P. E. Gómez, M. C. Casas Gómez, y I. Briceño Balcázar. «Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population». Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 47, n.º 2, mayo de 2018, pp. 277-88, doi:10.15446/rcciquifa.v47n2.73971.

Turabian

Ariza Márquez, Yeimy Viviana, Fabio Ancízar Aristizábal Gutiérrez, Alberto Gómez- Gutiérrez, Piedad Elena Gómez, María Consuelo Casas Gómez, y Ignacio Briceño Balcázar. «Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population». Revista Colombiana de Ciencias Químico-Farmacéuticas 47, no. 2 (mayo 1, 2018): 277–288. Accedido marzo 22, 2026. https://revistas.unal.edu.co/index.php/rccquifa/article/view/73971.

Vancouver

1.
Ariza Márquez YV, Ancízar Aristizábal Gutiérrez F, Gómez- Gutiérrez A, Gómez PE, Casas Gómez MC, Briceño Balcázar I. Frequency of 14 genetic variants associated with breast cancer risk and treatment in a Colombian population. Rev. Colomb. Cienc. Quím. Farm. [Internet]. 1 de mayo de 2018 [citado 22 de marzo de 2026];47(2):277-88. Disponible en: https://revistas.unal.edu.co/index.php/rccquifa/article/view/73971

Descargar cita

CrossRef Cited-by

CrossRef citations1

1. Jing Huey Chin, Shaheen Mansori, Angelo Brandelli Costa. (2019). Theory of Planned Behaviour and Health Belief Model: females’ intention on breast cancer screening. Cogent Psychology, 6(1) https://doi.org/10.1080/23311908.2019.1647927.

Dimensions

PlumX

Visitas a la página del resumen del artículo

854

Descargas

Los datos de descargas todavía no están disponibles.

Licencia

Derechos de autor 2018 Revista Colombiana de Ciencias Químico-Farmacéuticas

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia  autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.

Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13